The European Patent Office grants patent for RCD405
The European Patent Office (EPO) has announced that it intends to grant Respiratorius the patent application for the RESP9000 series, which includes the drug candidate RCD405, (European Patent Application No. 19740090.6 NOVEL BRONCHODILATING HETERO-LINKED AMIDES). After the formal fees have been paid, the patent will be granted, which gives Respiratorius market exclusivity in Europe until 2039. This is the first approval for the patent family.The RESP9000 series includes substances with the potential to be developed into drugs for the treatment of chronic obstructive pulmonary disease (COPD)